Manhattan Pharmaceuticals Acquires Hedrin(TM) for the Treatment of Head Lice
2007年6月27日 - 9:59PM
PRニュース・ワイアー (英語)
NEW YORK, JUNE 27 /PRNewswire-FirstCall/ -- Manhattan
Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has
acquired exclusive, North American rights to develop and
commercialize Hedrin(TM), a novel, non-insecticide product
candidate for the treatment of head lice. Hedrin is currently
marketed in Europe and in the United Kingdom (UK), and according to
market research firm Information Resources, Inc. has recently
achieved significant market share (greater than or equal to 40%) in
certain European countries. The product candidate is the third to
be licensed by Manhattan Pharmaceuticals from Thornton & Ross
Limited -- the largest independent OTC pharmaceutical manufacturer
in the UK. Hedrin is a non-insecticide combination of silicones
(dimeticone and cyclomethicone) that acts as a pediculicidal (lice
killing) agent by disrupting the osmotic balance within the insect.
Most currently available lice treatments contain chemical
insecticide. Because Hedrin kills lice physically rather than by
acting on the central nervous system the insects cannot build up
resistance to the treatment. Both silicones in Hedrin are used
extensively in cosmetics and toiletries. In a Phase 3, randomized,
controlled equivalence, clinical study conducted in Europe, Hedrin
was administered to 253 adult and child subjects with head louse
infestation. The study results, published in the British Medical
Journal in June 2005, demonstrated Hedrin's equivalence when
compared to the insecticide treatment, phenothrin, the most
widely-used pediculicide in the UK. In addition, according to the
same study, the Hedrin-treated subjects experienced significantly
less irritation (2%) than those treated with phenothrin (9%). A
more recent randomized, controlled parallel group superiority
clinical study (currently awaiting publication) has demonstrated
that Hedrin is superior to malathion liquid in the treatment of
head louse infestation. In addition to killing lice, further
analysis from both of the above clinical trials shows that Hedrin
is effective in killing louse eggs. "Hedrin is rapidly gaining
market acceptance in Europe and in the UK, where it has achieved
40% market share, and we believe it has the potential to provide an
important treatment alternative here in North America," stated Doug
Abel, president and chief executive officer. "The acquisition of
exclusive North American rights to Hedrin is another important step
in Manhattan Pharmaceuticals' corporate strategy to create a
robust, dual focused pipeline in the areas of
dermatology/immunology and endocrinology/metabolism." According to
the American Academy of Pediatrics an estimated 6-12 million
Americans are infested with head lice each year, with pre-school
and elementary age children, 3-11, and their families affected most
often. Recent studies have indicated that insecticide resistance
may be increasing and therefore contributing to treatment failure.
Accordingly, Manhattan Pharmaceuticals believes that there is
significant potential for a convenient, non-insecticide treatment
alternative. This licensing transaction increases the Manhattan
Pharmaceuticals pipeline to six clinical stage product candidates.
About Manhattan Pharmaceuticals, Inc. Manhattan Pharmaceuticals,
Inc., (AMEX:MHA) is a clinical-stage pharmaceutical company
developing novel, high-value drug candidates primarily in the areas
of endocrine/metabolic disease and dermatologic/immunologic
disorders. With a pipeline consisting of six clinical-stage product
candidates, Manhattan Pharmaceuticals is developing potential
therapeutics for large, underserved patient populations seeking
superior treatments for conditions including common obesity, morbid
obesity, psoriasis, and atopic dermatitis (eczema).
(http://www.manhattanpharma.com/) About Thornton & Ross Limited
Founded in Huddersfield, Thornton & Ross (T&R) is a
privately-owned company which has grown to become a significant
player within the UK healthcare market with brands which span the
Rx, OTC and consumer sectors. Its leading brands include COVONIA
(cough cold and flu range), HEDRIN (Headlice treatment), CARE
(range of everyday medicines), ALGESAL and TRANSVASIN (topical
analgesics), SETLERS and GASTROCOTE (heartburn and indigestion
remedies). T&R's leading household brand is ZOFLORA a range of
floral disinfectants. T&R manufactures the majority of its
products, specializing in pharmaceutical liquids and creams. The
company employs 350 people and has a turnover approaching 40
million pounds Sterling. (http://www.thorntonross.com/) Contact
Information Manhattan Pharmaceuticals, Inc. Michael G. McGuinness
Chief Financial Officer 212.582.3950 Thornton & Ross Limited
Dieno George Chief Executive Officer +44 (01484) 842217 Note
Regarding Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve
risks and uncertainties that could cause Manhattan Pharmaceutical's
actual results to differ materially from the anticipated results
and expectations expressed in these forward-looking statements.
These statements are often, but not always, made through the use of
words or phrases such as "anticipates," "expects," "plans,"
"believes," "intends," and similar words or phrases. These
statements are based on current expectations, forecasts and
assumptions that are subject to risks and uncertainties, which
could cause actual outcomes and results to differ materially from
these statements. Among other things, there can be no assurances
that any of Manhattan's development efforts relating to Hedrin(TM)
or any of its other product candidates will be successful. Other
risks that may affect forward-looking information contained in this
press release include the possibility of being unable to obtain
regulatory approval of Manhattan's product candidates, including
Hedrin(TM), the risk that the results of clinical trials may not
support Manhattan's claims, the risk that a non-insecticide
alternative treatment may not achieve market acceptance in North
America, Manhattan's reliance on third-party researchers to develop
its product candidates, and its lack of experience in developing
and commercializing pharmaceutical products. Additional risks are
described in the company's filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-KSB for the year
ended December 31, 2006. Manhattan assumes no obligation to update
these statements, except as required by law. DATASOURCE: Manhattan
Pharmaceuticals, Inc. CONTACT: Michael G. McGuinness, Chief
Financial Officer of Manhattan Pharmaceuticals, Inc.,
+1-212-582-3950; or Dieno George, Chief Executive Officer of
Thornton & Ross Limited, +44-01484-842217, , for Manhattan
Pharmaceuticals, Inc. Web site: http://www.manhattanpharma.com/
http://www.thorntonross.com/
Copyright
Manhattan Pharmaceuticals (AMEX:MHA)
過去 株価チャート
から 5 2024 まで 6 2024
Manhattan Pharmaceuticals (AMEX:MHA)
過去 株価チャート
から 6 2023 まで 6 2024